Thyrocare Technologies Ltd

Docon Technologies Private Limited, a promoter and holding company of Thyrocare Technologies Limited, has sold 1,57,69,696 equity shares, representing approximately 9.9% of the total paid-up share capital. This sale reduces Docon's shareholding from 60.92% to 51.02%. The transaction was conducted off-market. Docon Technologies is a wholly owned subsidiary of API Holdings Limited. Following the sale, Docon continues to remain the promoter and holding company of Thyrocare.

Docon Technologies Pvt Ltd, a promoter of Thyrocare Technologies Ltd, has announced the release of a pledge on 1,75,00,000 equity shares. These shares, representing 10.99% of the total equity, were previously encumbered in favor of Catalyst Trusteeship Limited as security for Non-Convertible Debentures (NCDs) issued by API Holdings Limited, Docon's holding company. The outstanding principal amount of these NCDs is INR 10,500 million. Following the release, Docon's encumbered shareholding in Thyrocare has reduced to 49.93%. This disclosure is made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Thyrocare Technologies Limited has announced that Docon Technologies Private Limited, a promoter, has sold 1,57,69,696 equity shares, representing approximately 9.90% of the company's paid-up equity share capital. The sale occurred through market trades on August 13, 2026. Following this transaction, Docon remains a promoter, and its shareholding in Thyrocare has reduced from 60.92% to 51.02%. The settlement of the transaction will be conducted in compliance with applicable laws and regulations. This disclosure impacts the promoter shareholding structure of the company.

Thyrocare Technologies Ltd announced that its promoter, Docon Technologies Private Limited, has released a pledge on 1,75,00,000 equity shares. The pledge was released by Catalyst Trusteeship Limited, acting as Debenture Trustee, on August 11, 2026. This release pertains to security for Non-Convertible Debentures issued by API Holdings Limited, Docon's holding company. Docon previously held 60.92% of Thyrocare's equity, with a significant portion encumbered. The disclosure was made pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Thyrocare Technologies Limited has informed the exchange about the resubmission of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. This action is in compliance with a request from the National Stock Exchange of India (NSE) to provide the results in a machine-readable format, as per NSE circular NSE/CML/2018/02. The company had previously submitted these results on July 23, 2026, following a Board Meeting. The resubmission includes the Limited Review Reports. Price Waterhouse Chartered Accountants LLP has provided a review conclusion stating that nothing has come to their attention to suggest the results are not prepared in accordance with Ind AS 34 and Listing Regulations, and do not contain material misstatements.

Thyrocare Technologies Ltd's Board of Directors has granted in-principle approval to evaluate a proposed restructuring of its wholly-owned subsidiary, Nuelear Healthcare Limited (NHL). NHL is involved in advanced cancer diagnostics, nuclear medicine, PET-CT and CT imaging, and radiopharmaceutical manufacturing. The restructuring could involve a demerger of NHL's radiology business undertaking outside the group, through mechanisms like a scheme of arrangement, slump sale, or business transfer. This evaluation is at an initial stage, and detailed terms will be presented to NHL's board later. The company will adhere to all regulatory requirements throughout the process.

Thyrocare Technologies Ltd announced the re-appointment of M/s. Ernst & Young LLP, Chartered Accountants, as its Internal Auditors for the Financial Year 2026-27. This decision was approved by the Board of Directors at their meeting held on July 23, 2026, based on the recommendation of the Audit Committee. The Board also approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report. The Board meeting commenced at 2:45 PM and concluded at 3:35 PM. The disclosures are available on the company's website.

Thyrocare Technologies Ltd announced its unaudited financial results for the quarter ended June 30, 2027 (Q1FY27), reporting a consolidated revenue of ₹240.02 Cr, a 24% year-on-year increase. The company's Profit After Tax (PAT) surged by 34% YoY to ₹51.33 Cr, with EBITDA also growing 34% YoY to ₹77.27 Cr. This strong performance was driven by a 26% YoY growth in the Pathology segment, which saw franchise revenue increase by 27% and partnership revenue by 26%. Thyrocare processed 55.2 million tests, a 28% YoY growth, reinforcing its market leadership. The company also expanded into Specialty Diagnostics, including Allergy and Genomics, and maintained high-quality standards with reduced complaints and improved turnaround times.

Thyrocare Technologies Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results along with the Limited Review Report. The company also approved the re-appointment of M/s. Ernst & Young LLP as Internal Auditors for the Financial Year 2026-27. The disclosures are available on the company's website.

Thyrocare Technologies opened FY27 with a broad-based beat: consolidated revenue from operations rose 24.3% YoY to ₹240.02 Cr and profit for the period grew 34.1% to ₹51.33 Cr (owners' share ₹52.19 Cr), with net margin firming to ~21.4% from 19.4% a year ago. The print runs comfortably ahead of the 'mid- to high-teens' revenue growth management guided on the Q4 concall and the 15–22% FY27 PAT growth analysts were modelling, and confirms the confident, volume-led tone (75% volume / 25% mix, no price hikes) set on that call. Standalone tells the same story — revenue +26.1% to ₹225.66 Cr, PAT +39.2% to ₹50.17 Cr — so there is no divergence between the two bases. The engine is the core diagnostic testing business: segment revenue rose 26.9% YoY to ₹226.21 Cr and segment profit jumped ~38% to ₹61.90 Cr, driving the operating-margin expansion (OPM ~32.2% vs 29.9% YoY). Imaging remains the soft spot — revenue slipped to ₹13.48 Cr from ₹14.04 Cr and contributed a thin ₹1.26 Cr result. Against the prior quarter the picture is a sequential slowdown rather than acceleration: revenue is up only 7.2% and PAT up 5.4% QoQ, and headline OPM eased from Q4's 33.5%, consistent with management's stated intent to reinvest operating leverage back into growth rather than let it drop to margin, keeping normalized EBITDA around 34%. The quarter also carried a cluster of governance actions: Price Waterhouse Chartered Accountants LLP reviewed these results as the newly appointed statutory auditor (per the 30 June appointment), EY was re-appointed internal auditor for FY27, and the board had earlier set a 23 June record date for the FY26 final dividend. One drag to watch is the subsidiary layer — unreviewed subsidiaries posted a ₹0.84 Cr comprehensive loss and non-controlling interest turned negative (₹0.86 Cr), which is why group profit for the period sits below the owners' share. Management's promised specialty-diagnostics foray (genomics, allergy) is not yet visible as a separate driver in this print.